Seth Wander, MD, PhD

He completed his undergraduate degree at Cornell University, where he studied molecular and cell biology and graduated magna cum laude with distinction in research. He earned his medical degree and doctorate in cancer biology at the University of Miami. Dr. Wander completed his internship and residency in internal medicine at the Massachusetts General Hospital and his fellowship training in medical oncology at the Dana-Farber Cancer Institute and the Massachusetts General Hospital Cancer Center.

Active in both the clinic and laboratory, Dr. Lander’s research interests involve genomic mechanisms of resistance to targeted therapies in metastatic breast cancer. He has published more than 40 peer-reviewed manuscripts focused on precision medicine and related topics in oncology. His research applies genetic and molecular sequencing results to understand how cancers become resistant to standard therapies, aiming to develop novel, personalized treatment strategies.

Dr. Wander is also an assistant professor of medicine at Harvard Medical School and remains engaged in teaching medical students, residents, and fellows. As part of a multidisciplinary team, he leads a various clinical trials focused on developing novel clinical strategies for patients with metastatic breast cancer and resistance to standard hormonal and targeted agents. He has presented educational sessions and original research both nationally and internationally on drug resistance and the development of personalized treatment strategies for breast cancer.

He was a recipient of the 2017 Dana-Farber Cancer Institute Wong Family Translational Research Award and a 2018 recipient of the Conquer Cancer Foundation/American Society of Clinical Oncology Young Investigator Award.